CMMB

Chemomab Therapeutics Ltd.

A clinical-stage biotechnology company developing antibody therapies for fibro-inflammatory diseases—conditions that combine inflammation with tissue scarring. Its lead drug, nebokitug, targets a protein called CCL24 to treat liver and skin conditions like primary sclerosing cholangitis. Founded in 2011 by scientist Adi Mor, the company's name blends "chemokine" (its target protein family) with "-mab," the standard suffix for monoclonal antibodies.

Sponsored American Depositary Shares (ADS)